Ketamine initiates rapid neuroplasticity. Dextromethorphan amplifies and extends those effects. Fluoxetine keeps both compounds active longer, allowing the full formula to work as one cohesive system. No single ingredient achieves this alone. Together, they represent a meaningful step forward in what ketamine treatment can offer.
Ketamine blocks the N-methyl-D-aspartate receptor in the brain, triggering rapid neuroplasticity — the brain’s remarkable ability to reorganize its structure, functions, and neural connections in the prefrontal cortex. Based on the extensive medical literature and Dr. Hebig’s direct clinical observation, this mechanism produces antidepressant effects significantly faster than conventional treatments.
Ketamine also upregulates Brain Derived Neurotrophic Factor, which research associates with its longer-lasting antidepressant effects. At treatment doses, ketamine paradoxically stimulates glutamate transmission, promoting synaptogenesis — the biological process of forming new synaptic connections between neurons in the nervous system. This process is crucial for brain development, memory, and learning.
Dextromethorphan works through the same NMDA receptor pathway as ketamine, amplifying glutamate release and promoting synaptogenesis in the prefrontal cortex. It also acts as a sigma-1 receptor agonist, which may enhance neuroprotection and mood regulation, and it inhibits the reuptake of serotonin and norepinephrine, contributing a further antidepressant dimension.
Based on its mechanism of action and Dr. Hebig’s clinical observation, dextromethorphan extends and deepens the therapeutic effects that ketamine initiates, supporting relief that reaches further and lasts longer than ketamine alone.
Dextromethorphan is rapidly metabolized by the cytochrome P450 enzyme CYP2D6. Fluoxetine is a potent inhibitor of CYP2D6. When all three compounds are administered together, the metabolism of dextromethorphan and ketamine is slowed, increasing their plasma concentrations and prolonging their therapeutic effects.
This is the mechanism that allows Brightiva to offer what ketamine alone can not. The precise combination of these three compounds, and the clinical protocol built around them, represent Dr. Hebig’s years of refinement in direct patient care.